Fig. 7.

CUDC-907 synergistically sensitizes breast cancer cells to TRAIL partially depend on DR5. a Cells were treated with the indicated concentrations of CUDC-907 for 24 h. The protein levels of XIAP, Bcl-xL, Bcl-2 and Bax were determined by Western blotting analysis. β-Actin was used as a loading control. b Expressions of DR4 and DR5 were determined using Western blotting analysis. c Knockdown of DR5 inhibits cytotoxicity after co-treatment with CUDC-907 and TRAIL. Following transfection with DR5 siRNA (Si-DR5) and control siRNA (Si-Con), cells were co-treated with CUDC-907 (50 nM) and TRAIL (80 ng/mL), cell cytotoxicity was examined by CCK-8 assay. Each bar corresponds to the mean ± SD for three independent experiments. *P < 0.05 as compared to control siRNA group. d The expression of DR5 and cleavage of caspase-8, −9 and PARP were measured by Western blotting assay. β-Actin was used as a loading control